komodo market signalsPCOS Isn’t the Story, What GLP-1s Are Doing to PCOS Is

GLP-1s are already reshaping obesity and diabetes. The next opportunities may come from the markets they quietly reshape afterward.

PCOS is one of the earliest examples. Across more than one million newly diagnosed patients, GLP-1 adoption grew 564%. But the more interesting finding wasn’t the growth. It was what changed around it — generalists displacing specialists, downstream care patterns shifting, second-order effects emerging before they show up in guidance or consensus.

If you’re evaluating companies exposed to GLP-1s, women’s health, or fertility, this is an early look at a market that may already be moving.

For informational purposes only. Does not constitute investment advice.